Selective Serotonin Reuptake Inhibitors May Reduce Treatment-Associated Depression in HCV Patients
November 13, 2013
This article was reported by Healio.
An article in Healio presents a study on the use of selective serotonin reuptake inhibitors (SSRIs) to treat depression resulting from the use of pegylated interferon alfa-2a or -2b (Peg-IFN a-2a or a-2b) with ribavirin combination treatment for chronic hepatitis C virus (HCV) infection. Peg-IFN a-2a or a-2b with ribavirin treatment is considered a very effective HCV treatment. However, this treatment is associated with a 70-percent incidence of mild to moderate depression and a 20- to 40-percent incidence of major depression in chronic HCV patients.
Researchers, including Yan-Yan Yu, MD, of the department of infectious diseases at China's Peking University, performed a meta-analysis of six randomized, double-blind, placebo-controlled trials with 522 chronic HCV patients who had received Peg-IFN a-2a or a-2b with ribavirin. Those participants who were treated with SSRIs received escitalopram, citalopram, or paroxetine.View Full Article
Add Your Comment:
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before
adding your comment, please read TheBody.com's Comment Policy.)